FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050906403> ?p ?o ?g. }

• W2050906403 endingPage "213" @default.
• W2050906403 startingPage "201" @default.
• W2050906403 abstract "Background Gabapentin enacarbil, a transported acyloxyalkylcarbamate prodrug of gabapentin, provides predictable and dose-proportional gabapentin exposure (AUC). Gabapentin is cleared via renal excretion, and its elimination is proportional to creatinine clearance (CrCL); CrCL can, therefore, be used as a predictor of gabapentin renal clearance. Gabapentin produced from hydrolysis of gabapentin enacarbil is also eliminated via the renal clearance pathway. It was, therefore, anticipated that the pharmacokinetics of gabapentin derived from gabapentin enacarbil would also be affected by renal function. Objective The objective of this study was to describe a population pharmacokinetic analysis of gabapentin enacarbil in patients with varying degrees of renal function, using data from an open-label study of gabapentin enacarbil in patients with renal impairment (XenoPort, Inc. protocol XP066), to determine whether dosage adjustments are necessary in patients with renal impairment. Methods Men and women >18 years of age with a body mass index ≤34 kg/m2 and who were, in general, healthy with the exception of renal impairment were enrolled All patients received a single 600-mg gabapentin enacarbil extended-release tablet under fed conditions. After dosing, plasma, urine, and dialysate samples were analyzed. Safety profile evaluations included adverse events, vital signs, ECGs, and laboratory values. Pharmacokinetic data were compared with those from Phase I–III studies in subjects with normal renal function to evaluate the relationship between gabapentin oral clearance (CL/F) and CrCL. Results Fifteen patients (11 men and 4 women) were enrolled. One patient had moderate renal impairment (CrCL 30–59 mL/min), 7 patients had severe renal impairment (CrCL <30 mL/min), and 7 patients had end-stage renal disease (CrCL <15 mL/min). Ten patients were white, 4 were African American, and 1 was American Indian or Alaskan Native. Their mean (range) age was 55 (28–76) years, weight was 85.6 (62–134) kg, and body mass index was 28.3 (22–34) kg/m2. Mean maximum plasma gabapentin concentration was 5.77 μg/mL in patients with moderate and severe renal impairment, and 5.59 μg/mL in patients with end-stage renal disease who were undergoing hemodialysis. Based on the population pharmacokinetic analysis, gabapentin CL/F after administration of gabapentin enacarbil was proportionally related to CrCL, with an approximately 1.6-fold decrease in CL/F for every 2-fold decrease in CrCL. The most frequent adverse event was dizziness (4 of 15 patients). Other adverse events that were assessed as possibly or probably related to treatment were defecation urgency, extremity pain, feeling of relaxation, and muscle weakness; each occurred in 1 patient only. All events were mild or moderate and resolved without sequelae. Conclusions The data suggest that dosage adjustment for gabapentin enacarbil is necessary in patients with impaired renal function. Gabapentin enacarbil, 600 mg, seemed to be well tolerated in this small selected population." @default.
• W2050906403 created "2016-06-24" @default.
• W2050906403 creator A5005526580 @default.
• W2050906403 creator A5012951977 @default.
• W2050906403 creator A5040665740 @default.
• W2050906403 creator A5052522360 @default.
• W2050906403 creator A5072785251 @default.
• W2050906403 creator A5078465675 @default.
• W2050906403 creator A5079505944 @default.
• W2050906403 date "2012-01-01" @default.
• W2050906403 modified "2023-10-10" @default.
• W2050906403 title "Clinical Pharmacokinetics of Gabapentin After Administration of Gabapentin Enacarbil Extended-Release Tablets in Patients With Varying Degrees of Renal Function Using Data From an Open-Label, Single-Dose Pharmacokinetic Study" @default.
• W2050906403 cites W1529126315 @default.
• W2050906403 cites W1535948728 @default.
• W2050906403 cites W1547646341 @default.
• W2050906403 cites W1550111394 @default.
• W2050906403 cites W1964859514 @default.
• W2050906403 cites W1967715258 @default.
• W2050906403 cites W1975325237 @default.
• W2050906403 cites W1985008430 @default.
• W2050906403 cites W1987371922 @default.
• W2050906403 cites W1991024180 @default.
• W2050906403 cites W1995716893 @default.
• W2050906403 cites W2014297535 @default.
• W2050906403 cites W2027339686 @default.
• W2050906403 cites W2039982019 @default.
• W2050906403 cites W2051303382 @default.
• W2050906403 cites W2057983296 @default.
• W2050906403 cites W2065434413 @default.
• W2050906403 cites W2068123007 @default.
• W2050906403 cites W2088812259 @default.
• W2050906403 cites W2091353989 @default.
• W2050906403 cites W2091605545 @default.
• W2050906403 cites W2103475556 @default.
• W2050906403 cites W2124516214 @default.
• W2050906403 cites W2156260991 @default.
• W2050906403 cites W2169879202 @default.
• W2050906403 cites W2300163045 @default.
• W2050906403 cites W4245528808 @default.
• W2050906403 cites W4247231670 @default.
• W2050906403 doi "https://doi.org/10.1016/j.clinthera.2011.12.004" @default.
• W2050906403 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22206794" @default.
• W2050906403 hasPublicationYear "2012" @default.
• W2050906403 type Work @default.
• W2050906403 sameAs 2050906403 @default.
• W2050906403 citedByCount "28" @default.
• W2050906403 countsByYear W20509064032012 @default.
• W2050906403 countsByYear W20509064032013 @default.
• W2050906403 countsByYear W20509064032014 @default.
• W2050906403 countsByYear W20509064032015 @default.
• W2050906403 countsByYear W20509064032016 @default.
• W2050906403 countsByYear W20509064032017 @default.
• W2050906403 countsByYear W20509064032018 @default.
• W2050906403 countsByYear W20509064032019 @default.
• W2050906403 countsByYear W20509064032020 @default.
• W2050906403 countsByYear W20509064032022 @default.
• W2050906403 countsByYear W20509064032023 @default.
• W2050906403 crossrefType "journal-article" @default.
• W2050906403 hasAuthorship W2050906403A5005526580 @default.
• W2050906403 hasAuthorship W2050906403A5012951977 @default.
• W2050906403 hasAuthorship W2050906403A5040665740 @default.
• W2050906403 hasAuthorship W2050906403A5052522360 @default.
• W2050906403 hasAuthorship W2050906403A5072785251 @default.
• W2050906403 hasAuthorship W2050906403A5078465675 @default.
• W2050906403 hasAuthorship W2050906403A5079505944 @default.
• W2050906403 hasConcept C112705442 @default.
• W2050906403 hasConcept C126322002 @default.
• W2050906403 hasConcept C126894567 @default.
• W2050906403 hasConcept C142724271 @default.
• W2050906403 hasConcept C159641895 @default.
• W2050906403 hasConcept C204787440 @default.
• W2050906403 hasConcept C2776608144 @default.
• W2050906403 hasConcept C2777288759 @default.
• W2050906403 hasConcept C42219234 @default.
• W2050906403 hasConcept C71924100 @default.
• W2050906403 hasConcept C98274493 @default.
• W2050906403 hasConceptScore W2050906403C112705442 @default.
• W2050906403 hasConceptScore W2050906403C126322002 @default.
• W2050906403 hasConceptScore W2050906403C126894567 @default.
• W2050906403 hasConceptScore W2050906403C142724271 @default.
• W2050906403 hasConceptScore W2050906403C159641895 @default.
• W2050906403 hasConceptScore W2050906403C204787440 @default.
• W2050906403 hasConceptScore W2050906403C2776608144 @default.
• W2050906403 hasConceptScore W2050906403C2777288759 @default.
• W2050906403 hasConceptScore W2050906403C42219234 @default.
• W2050906403 hasConceptScore W2050906403C71924100 @default.
• W2050906403 hasConceptScore W2050906403C98274493 @default.
• W2050906403 hasIssue "1" @default.
• W2050906403 hasLocation W20509064031 @default.
• W2050906403 hasLocation W20509064032 @default.
• W2050906403 hasOpenAccess W2050906403 @default.
• W2050906403 hasPrimaryLocation W20509064031 @default.
• W2050906403 hasRelatedWork W1973741567 @default.
• W2050906403 hasRelatedWork W2010711991 @default.
• W2050906403 hasRelatedWork W2039736044 @default.
• W2050906403 hasRelatedWork W2064815289 @default.
• W2050906403 hasRelatedWork W2067628361 @default.
• W2050906403 hasRelatedWork W2093874596 @default.

• next